Clinical Trials Sponsored by Janssen Pharmaceuticals

Total 22181 results

University of California, San Francisco
Janssen Pharmaceuticals

Completed

Single Cell Genomics of Psoriatic Skin

Psoriasis

United States
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals

Recruiting

A Study of Amivantamab in People With Esophagogastric Cancer

Esophagogastric Cancer

United States
NEAT ID Foundation
Gilead Sciences; Janssen Pharmaceuticals

Active, not recruiting

The Late Presenter Treatment Optimisation Study (LAPTOP)

HIV/AIDS

Spain, Ireland, France, United Kingdom, Germany, Italy, Belgium
University of Alabama at Birmingham
Janssen Pharmaceuticals

Completed

Risperidone and Suicidality in Major Depressive Disorder

Depression

United States
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Yale University
Janssen Pharmaceutica N.V., Belgium

Completed

Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics

Diabetes Mellitus | Schizophrenia | Bipolar Disorder
Janssen Pharmaceutical K.K.
Mitsubishi Tanabe Pharma Corporation

Completed

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Janssen Pharmaceutical K.K.
Mitsubishi Tanabe Pharma Corporation

Completed

A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Rheumatoid Arthritis

Japan
Indiana University
Bristol-Myers Squibb; Pfizer; Janssen Pharmaceuticals

Completed

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism (MATHVTE)

Venous Thromboembolism

United States
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals

Terminated

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

HIV Infections | Acute HIV Infection

United States
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals

Completed

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

HIV Infections

United States
PETHEMA Foundation
Janssen-Cilag Ltd.; Mundipharma Pharmaceuticals B.V.

Completed

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Spain
Cancer Trials Ireland
Bristol-Myers Squibb; Janssen Pharmaceuticals

Active, not recruiting

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. (CPD-DARA)

Multiple Myeloma

Ireland
Janssen Pharmaceuticals

Completed

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

HIV Infections | Candidiasis, Esophageal

United States
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
University Hospital, Lille
Janssen Pharmaceutica N.V., Belgium

Not yet recruiting

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01)

Multiple Myeloma
University of Alabama at Birmingham
Janssen Pharmaceutica

Completed

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

Borderline Personality Disorder

United States
Centre for Human Drug Research, Netherlands
Janssen Pharmaceuticals

Recruiting

An Explorative Psoriasis Biomarker Study

Psoriasis Vulgaris

Netherlands
Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Major Depressive Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.

Anxiety Disorders
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States, India, Romania
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients

Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder

United States, India, Malaysia, Romania, Korea, Republic of, Philippines
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression

Depressive Disorder | Depression | Depressive Disorder, Major
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Insel Gruppe AG, University Hospital Bern
Bayer; Janssen Pharmaceuticals

Completed

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery (BARIVA)

Bariatric Surgery

Switzerland
MRC/UVRI and LSHTM Uganda Research Unit
Janssen Pharmaceuticals

Recruiting

Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)

HIV-1-infection

South Africa, Kenya, Uganda
Lindner Center of HOPE
University of Cincinnati; Janssen Pharmaceuticals

Completed

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

Bipolar Disorder | Anxiety Disorder

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Westfälische Wilhelms-Universität Münster
Janssen Pharmaceutica N.V., Belgium

Recruiting

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM)

Prostatic Neoplasms

Austria, Germany
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Completed

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Hellenic Society of Hematology
Takeda; Janssen Pharmaceutica NV

Unknown

Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (DARIA)

Multiple Myeloma

Greece
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Terminated

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Neuroma, Acoustic | Neurofibromatosis Type 2

United States
Jonsson Comprehensive Cancer Center
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 Plus Enasidenib for Relapsed AML

Recurrent Acute Myeloid Leukemia

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
ANRS, Emerging Infectious Diseases
Gilead Sciences; Janssen Pharmaceutica

Completed

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) (2LADY)

HIV Infections | HIV

Burkina Faso, Cameroon, Senegal

Clinical Trials Sponsored by Janssen Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations